Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | The next steps for tolebrutinib in MS

Erik Wallstroem, MD, PhD, Global Head of Development, Neurology and Opthalmology, Sanofi, and Tom Snow, VP, Global Franchise Head, Neurology and Rare Blood Disorders, Sanofi, discuss the next steps for tolebrutininb. Despite challenges like the global pandemic, the team has maintained its timeline. The resilience of both patients and investigators was acknowledged, particularly given the additional safety monitoring introduced recently and the unprecedented challenges faced. They emphasize the significant unmet need in MS treatment and the necessity of new treatments, which have been mirrored by the dedication of patients and investigators throughout these trials. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.